Effects of backbone cyclization on the pharmacokinetics and drug efficiency of the orally active analgesic conotoxin cVc1.1

de Veer, 2019, Cyclotides: from structure to function, Chem Rev, 119, 12375, 10.1021/acs.chemrev.9b00402 Wang, 2018, Designing macrocyclic disulfide-rich peptides for biotechnological applications, Nat Chem Biol, 14, 417, 10.1038/s41589-018-0039-y Góngora-Benítez, 2014, Multifaceted roles of disulfide bonds, Pept Therap Chem Rev, 114, 901, 10.1021/cr400031z Dutertre, 2014, Evolution of separate predation- and defence-evoked venoms in carnivorous cone snails, Nat Commun, 5, 3521, 10.1038/ncomms4521 Myers, 1993, Conus peptides as chemical probes for receptors and ion channels, Chem Rev, 93, 1923, 10.1021/cr00021a013 McIntosh, 1999, Conus peptides targeted to specific nicotinic acetylcholine receptor subtypes, An Rev Biochem, 68, 59, 10.1146/annurev.biochem.68.1.59 Terlau, 2004, Conus venoms: a rich source of novel ion channel-targeted peptides, Physiol Rev, 84, 41, 10.1152/physrev.00020.2003 Akondi, 2014, Discovery, synthesis, and structure–activity relationships of conotoxins, Chem Rev, 114, 5815, 10.1021/cr400401e Zoli, 2015, Diversity of native nicotinic receptor subtypes in mammalian brain, Neuropharmacol, 96, 302, 10.1016/j.neuropharm.2014.11.003 Jin, 2019, Conotoxins: chemistry and biology, Chem Rev, 119, 11510, 10.1021/acs.chemrev.9b00207 Robinson, 2014, Conotoxin gene superfamilies, Mar Drugs, 12, 6058, 10.3390/md12126058 Azam, 2009, Alpha-conotoxins as pharmacological probes of nicotinic acetylcholine receptors, Acta Pharmacol Sin, 30, 771, 10.1038/aps.2009.47 Callaghan, 2008, Analgesic α-conotoxins Vc1.1 and Rg1A inhibit N-type calcium channels in rat sensory neurons via GABAB receptor activation, J Neurosci, 28, 10943, 10.1523/JNEUROSCI.3594-08.2008 Adams, 2012, Analgesic conotoxins: block and G protein-coupled receptor modulation of N-type (CaV 2.2) calcium channels, Br J Pharmacol, 166, 486, 10.1111/j.1476-5381.2011.01781.x Olivera, 1987, Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using ω-conotoxin from Conus magus venom, Biochemistry., 26, 2086, 10.1021/bi00382a004 Atanassoff, 2000, Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain, Reg Anesth Pain Med, 25, 274 Kolosov, 2010, CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain, Pain Med, 11, 262, 10.1111/j.1526-4637.2009.00741.x Sandall, 2003, A novel α-conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo, Biochemistry, 42, 6904, 10.1021/bi034043e Jakubowski, 2004, Determining sequences and post-translational modifications of novel conotoxins in Conus victoriae using cDNA sequencing and mass spectrometry, J Mass Spectrom, 39, 548, 10.1002/jms.624 Satkunanathan, 2005, Alpha-conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones, Brain Res, 1059, 149, 10.1016/j.brainres.2005.08.009 Clark, 2010, The engineering of an orally active conotoxin for the treatment of neuropathic pain, Angew Chem Int Ed Engl, 49, 6545, 10.1002/anie.201000620 Pharmaceuticals, 2007 Azam, 2012, Molecular basis for the differential sensitivity of rat and human alpha9alpha10 nAChRs to alpha-conotoxin RgIA, J Neurochem, 122, 1137, 10.1111/j.1471-4159.2012.07867.x Pharmaceuticals, 2007 Castro, 2018, Cyclic analogues of α-conotoxin Vc1.1 inhibit colonic nociceptors and provide analgesia in a mouse model of chronic abdominal pain, Br J Pharmacol, 175, 2384, 10.1111/bph.14115 Craik, 2013, The future of peptide-based drugs, Chem Biol Drug Des, 81, 136, 10.1111/cbdd.12055 Blanchfield, 2007, Oral absorption and in vivo biodistribution of alpha-conotoxin MII and a lipidic analogue, Biochem Biophys Res Commun, 361, 97, 10.1016/j.bbrc.2007.06.138 Blanchfield, 2003, Synthesis, structure elucidation, in vitro biological activity, toxicity, and Caco-2 cell permeability of lipophilic analogues of alpha-conotoxin MII, J Med Chem, 46, 1266, 10.1021/jm020426j Nilsson, 2012, In situ mass spectrometry imaging and ex vivo characterization of renal crystalline deposits induced in multiple preclinical drug toxicology studies, PLoS One, 7, 10.1371/journal.pone.0047353 Castellino, 2011, MALDI imaging mass spectrometry: bridging biology and chemistry in drug development, Bioanalysis., 3, 2427, 10.4155/bio.11.232 Armishaw, 2011, Improving the stability of alpha-conotoxin AuIB through N-to-C cyclization: the effect of linker length on stability and activity at nicotinic acetylcholine receptors, Antioxid Redox Signal, 14, 65, 10.1089/ars.2010.3458 Lovelace, 2011, Stabilization of alpha-conotoxin AuIB: influences of disulfide connectivity and backbone cyclization, Antioxid Redox Signal, 14, 87, 10.1089/ars.2009.3068 Halai, 2011, Effects of cyclization on stability, structure, and activity of alpha-conotoxin RgIA at the alpha9alpha10 nicotinic acetylcholine receptor and GABA(B) receptor, J Med Chem, 54, 6984, 10.1021/jm201060r Cavaco, 2021, The challenge of peptide proteolytic stability studies: scarce data, difficult readability, and the need for harmonization, Angew Chem Int Ed, 60, 1686, 10.1002/anie.202006372 Braggio, 2010, Drug efficiency: a new concept to guide lead optimization programs towards the selection of better clinical candidates, Expert Opin Drug Discov., 5, 609, 10.1517/17460441.2010.490553 Valko, 2012, In vitro measurement of drug efficiency index to aid early lead optimization, J Pharm Sci, 101, 4155, 10.1002/jps.23305 Montanari, 2011, Application of drug efficiency index in drug discovery: a strategy towards low therapeutic dose, Expert Opin Drug Discov, 6, 913, 10.1517/17460441.2011.602968 Shackleford, 2016, Quantifying uncertainty in the ratio of two measured variables: a recap and example, J Pharm Sci, 105, 3462, 10.1016/j.xphs.2016.07.019 Nakai, 2004, Evaluation of the protein binding ratio of drugs by a micro-scale ultracentrifugation method, J Pharm Sci, 93, 847, 10.1002/jps.20012 Stalmans, 2014, Blood-brain barrier transport of short proline-rich antimicrobial peptides, Protein Pept Lett, 21, 399, 10.2174/09298665113206660110 Stalmans, 2015, Cell-penetrating peptides selectively cross the blood-brain barrier in vivo, PLoS One, 10, 10.1371/journal.pone.0139652 Vergote, 2008, In vitro metabolic stability of obestatin: kinetics and identification of cleavage products, Peptides., 29, 1740, 10.1016/j.peptides.2008.05.018 Gjedde, 1981, High- and low-affinity transport of D-glucose from blood to brain, J Neurochem, 36, 1463, 10.1111/j.1471-4159.1981.tb00587.x Patlak, 1983, Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data, J Cereb Blood Flow Metab, 3, 1, 10.1038/jcbfm.1983.1 Triguero, 1990, Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins, J Neurochem, 54, 1882, 10.1111/j.1471-4159.1990.tb04886.x Gutierrez, 1993, Murine tumor necrosis factor alpha is transported from blood to brain in the mouse, J Neuroimmunol, 47, 169, 10.1016/0165-5728(93)90027-V Banks, 1989, Quantifying carrier-mediated transport of peptides from the brain to the blood, Methods Enzymol, 168, 652, 10.1016/0076-6879(89)68047-0 Valko, 2017, In vitro membrane binding and protein binding (IAM MB/PB technology) to estimate in vivo distribution: applications in early drug discovery, ADMET & DMPK, 5, 14, 10.5599/admet.5.1.373 Caldwell, 2004, Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data?, Eur J Drug Metab Pharmacokinet, 29, 133, 10.1007/BF03190588 Van Dorpe, 2010, Analytical characterization and comparison of the blood-brain barrier permeability of eight opioid peptides, Peptides., 31, 1390, 10.1016/j.peptides.2010.03.029 Stalmans, 2015, Classification of peptides according to their blood-brain barrier influx, Protein Pept Lett, 22, 768, 10.2174/0929866522666150622101223 Smith, 2015, Volume of distribution in drug design, J Med Chem, 58, 5691, 10.1021/acs.jmedchem.5b00201 Jimenez-Andrade, 2008, Vascularization of the dorsal root ganglia and peripheral nerve of the mouse: implications for chemical-induced peripheral sensory neuropathies, Mol Pain, 4, 10, 10.1186/1744-8069-4-10 Colombo G. GABAB receptor. The Receptors. 1st ed. Cham: Springer International Publishing: Imprint: Humana. Serrats, 2017, GABAB receptor modulation-to B or not to be B a pro-cognitive medicine?, Curr Opin Pharmacol, 35, 125, 10.1016/j.coph.2017.09.012 Legg, 1987, Cyclosporin: measurement of fraction unbound in plasma, J Pharm Pharmacol, 39, 599, 10.1111/j.2042-7158.1987.tb03436.x Ptachcinski, 1986, Clinical pharmacokinetics of cyclosporin, Clin Pharmacokinet, 11, 107, 10.2165/00003088-198611020-00002 Wang, 2016, Biodistribution of the cyclotide MCoTI-II, a cyclic disulfide-rich peptide drug scaffold, J Pept Sci, 22, 305, 10.1002/psc.2862